1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 587
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Ms. Sasha Damouni Ellis | Executive VP & Chief Corporate Affairs Officer | N/A | N/A | N/A |
Dr. Carey Hwang M.D., Ph.D. | Senior VP of Clinical Research & Interim Chief Medical Officer | N/A | N/A | N/A |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 6. Die grundlegenden Scores sind Audit: 6, Vorstand: 4, Shareholderrechte: 8, Kompensation: 8.